Home › Cancer (all types) › NCT07903532

Multicenter Study for External Validation of the TB-NET Score

Multicentric Study for External Validation of the TB-NET Score

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.
* Grade 1, 2 or 3 if well-differentiated morphology for GEP-NETs. Typical or Atypical Lung Carcinoids.
* At least one target lesion.

Exclusion Criteria:

* Patients with Neuroendocrine Carcinomas.
* Patients with no target lesions (according to RECIST 1.1 criteria).

About the study

This is a retrospective, observational, multicenter study aiming to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or lung carcinoids. The primary objective is to validate the prognostic value of the TB-NET Score for progression-free survival (PFS). Secondary objectives include the evaluation of overall survival (OS), objective response rate (ORR), grade 3-4 adverse events, biochemical and functional imaging correlates, and the potential additional prognostic value of tumor growth rate (TGR).

Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Participants: 400 · Started: May 12, 2026

Contact the study team

• Angela Lamarca, MD, PhD · Phone: +34 915504800
• Diego Fernández, MD · Phone: +34 636284882

Official record on ClinicalTrials.gov — NCT07903532

Locations in the U.S.

Conditions

• Cancer (all types)
• Neuroendocrine Tumors

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.